A Phase 2 interventional study of E/C/F/TDF and E/C/F/TAF Placebo in Acquired Immunodeficiency Syndrome and HIV Infections, sponsored by Gilead Sciences. Completed at 41 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is the only one in phase 2, and was the 3rd registered.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →
Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2011; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 279 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 116 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2011, is one of 7 in phase 2, and was the 22nd registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
Drug: E/C/F/TAF · Drug: E/C/F/TDF Placebo
E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
Drug: E/C/F/TDF · Drug: E/C/F/TAF Placebo
Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase. Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase.
Drug: E/C/F/TAF
150/150/200/300 mg FDC tablet administered orally once daily
Also known as: Stribild®
Tablet administered orally once daily
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily
Also known as: Genvoya®
Tablet administered orally once daily
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in log10 HIV-1 RNA at Weeks 24 and 48
Time frame: Baseline; Weeks 24 and 48
Change From Baseline in CD4+ Cell Count at Weeks 24 and 48
Time frame: Baseline; Weeks 24 and 48
Participants were enrolled at study sites in the United States and Puerto Rico. The first participant was screened on 28 December 2011. The last study visit occurred on 22 August 2016.
| Milestone | E/C/F/TAF | E/C/F/TDF | D/C/F/TAF to Open-Label E/C/F/TAF | DRV+COBI+TVD to Open-Label E/C/F/TAF |
|---|---|---|---|---|
| Started | 113 | 58 | 0 | 0 |
| Completed | 107 | 53 | 0 | 0 |
| Not completed | 6 | 5 | 0 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 0 | 0 |
| Withdrew: Subject non-compliance | 0 | 1 | 0 | 0 |
| Milestone | E/C/F/TAF | E/C/F/TDF | D/C/F/TAF to Open-Label E/C/F/TAF | DRV+COBI+TVD to Open-Label E/C/F/TAF |
|---|---|---|---|---|
| Started | 105 | 53 | 70 | 38 |
| Completed | 86 | 46 | 61 | 33 |
| Not completed | 19 | 7 | 9 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 8 | 3 | 2 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 9 | 3 | 5 | 5 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 | 88.4 | 89.7 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | 88.4 | 87.9 |
| log10 copies/mL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Baseline | 4.63 ± 0.572 | 4.69 ± 0.577 |
| Change at Week 24 | -3.20 ± 0.654 | -3.26 ± 0.606 |
| Change at Week 48 | -3.22 ± 0.606 | -3.33 ± 0.572 |
| cells/uL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Baseline | 404 ± 181.6 | 394 ± 209.6 |
| Change at Week 24 | 165 ± 115.6 | 179 ± 127.7 |
| Change at Week 48 | 177 ± 144.1 | 204 ± 120.4 |
Collected over Up to 186.2 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF | — | 12/112 (10.7%) | 91/112 (81.3%) |
| E/C/F/TDF | — | 3/58 (5.2%) | 48/58 (82.8%) |
| All E/C/F/TAF | — | 35/273 (12.8%) | 215/273 (78.8%) |
| Event | E/C/F/TAF | E/C/F/TDF | All E/C/F/TAF |
|---|---|---|---|
| DepressionPsychiatric disorders | 1/112 | 2/58 | 3/273 |
| Suicidal ideationPsychiatric disorders | 1/112 | 2/58 | 2/273 |
| Large intestine perforationGastrointestinal disorders | 0/112 | 1/58 | 0/273 |
| Clostridium difficile colitisInfections and infestations | 0/112 | 1/58 | 0/273 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/112 | 1/58 | 0/273 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/112 | 1/58 | 0/273 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/112 | 1/58 | 0/273 |
| AppendicitisInfections and infestations | 0/112 | 0/58 | 4/273 |
| Bipolar disorderPsychiatric disorders | 1/112 | 0/58 | 3/273 |
| Acute myocardial infarctionCardiac disorders | 1/112 | 0/58 | 2/273 |
| Event | E/C/F/TAF | E/C/F/TDF | All E/C/F/TAF |
|---|---|---|---|
| NauseaGastrointestinal disorders | 25/112 | 7/58 | 35/273 |
| Upper respiratory tract infectionInfections and infestations | 17/112 | 12/58 | 60/273 |
| DiarrhoeaGastrointestinal disorders | 19/112 | 9/58 | 40/273 |
| FatigueGeneral disorders | 18/112 | 5/58 | 29/273 |
| SyphilisInfections and infestations | 5/112 | 3/58 | 38/273 |
| Back painMusculoskeletal and connective tissue disorders | 3/112 | 8/58 | 27/273 |
| HeadacheNervous system disorders | 11/112 | 8/58 | 26/273 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/112 | 6/58 | 36/273 |
| BronchitisInfections and infestations | 7/112 | 3/58 | 33/273 |
| NasopharyngitisInfections and infestations | 7/112 | 2/58 | 31/273 |
E/C/F/TAF and E/C/F/TDF arms: participants who were randomized to the Double-Blind Phase and received at least 1 dose of study drug. D/C/F/TAF to E/C/F/TAF and DRV+COBI+TVD to E/C/F/TAF arms: participants who enrolled from Gilead-sponsored Study GS-US-299-0102 in the Open-Label Extension Phase and received at least 1 dose of open-label E/C/F/TAF
| Age, Continuous(years) | E/C/F/TAF | E/C/F/TDF | D/C/F/TAF to Open-Label E/C/F/TAF | DRV+COBI+TVD to Open-Label E/C/F/TAF | Total |
|---|---|---|---|---|---|
| Mean | 35 ± 11.3 | 37 ± 10.6 | 36 ± 11.2 | 37 ± 10.7 | 36 ± 11.0 |
| Sex: Female, Male(Participants) | E/C/F/TAF | E/C/F/TDF | D/C/F/TAF to Open-Label E/C/F/TAF | DRV+COBI+TVD to Open-Label E/C/F/TAF | Total |
|---|---|---|---|---|---|
| Female | 4 | 1 | 3 | 3 | 11 |
| Male | 108 | 57 | 67 | 35 | 267 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2011 to primary completion in Oct 2012, 9 months.
Results were first posted in Jan 2016, 3 years 2 months after primary completion. A results delay was requested in Oct 2013.
Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 9 months is below that.
Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →